Apogee Therapeutics, Inc.
APGE
$56.15
$0.110.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.46M | 16.71M | 15.65M | 12.97M | 10.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.17M | 63.10M | 75.88M | 58.69M | 44.12M |
| Operating Income | -73.17M | -63.10M | -75.88M | -58.69M | -44.12M |
| Income Before Tax | -66.02M | -55.26M | -67.20M | -49.02M | -33.82M |
| Income Tax Expenses | 72.00K | 83.00K | 18.00K | -- | -- |
| Earnings from Continuing Operations | -66.10M | -55.34M | -67.22M | -49.02M | -33.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.10M | -55.34M | -67.22M | -49.02M | -33.82M |
| EBIT | -73.17M | -63.10M | -75.88M | -58.69M | -44.12M |
| EBITDA | -72.77M | -62.89M | -75.81M | -58.64M | -44.09M |
| EPS Basic | -1.13 | -0.95 | -1.17 | -0.86 | -0.60 |
| Normalized Basic EPS | -0.71 | -0.59 | -0.73 | -0.54 | -0.37 |
| EPS Diluted | -1.13 | -0.95 | -1.17 | -0.86 | -0.60 |
| Normalized Diluted EPS | -0.71 | -0.59 | -0.73 | -0.54 | -0.37 |
| Average Basic Shares Outstanding | 58.43M | 58.20M | 57.25M | 56.80M | 56.52M |
| Average Diluted Shares Outstanding | 58.43M | 58.20M | 57.25M | 56.80M | 56.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |